Abemaciclib (Verzenios)
- Status:
- Red
- Decision Date:
- March 2019
Comments
RED:
- NICE TA563 - with aromatase inhibitor for previously untreated hormone receptor-positive, HER2 negative, locally advanced or metastatic breast cancer. (Decision date - March 2019)
- NICE TA579 - with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine therapy. (Decision date - June 2019)
- NICE TA725 - Abemaciclib with fulvestrant for treating hormone
receptor-positive, HER2-negative advanced breast cancer after endocrine therapy. This guidance updates
and replaces NICE TA579 (Decision date - Oct 2021)
- NICE TA810 - Abemaciclib with endocrine therapy for adjuvant treatment
of hormone receptor-positive, HER2-negative, node-positive early breast cancer
at high risk of recurrence (Decision date - August 2022)
Red Drug Classifications
- 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
- 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
- 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
- 8. NHS England commissioned – to be used in line with NHSE commissioning intentions
search again